Expert Interview
A Second View: Discussing the potential of CD20 as class in treating Multiple Sclerosis with a focus on BRIUMVI, Kesimpta, and Ocrevus
Ticker(s): TGTX, NVS, RHHBYInstitution: UPenn
- Director Emeritus, Multiple Sclerosis Center and Associate Professor of Neurology at the University of Pennsylvania.
- Treats 1500 patients with Multiple Sclerosis.
- Clinical expertise include Multiple Sclerosis (MS), Parkinsons, Myasthenia Gravis and other neuromuscular diseases; Research interest focuses on the development of new compounds for the treatment of multiple sclerosis (MS) and the utilization of new MRI techniques to study MS pathogenesis and immunology.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
